Targanta Raising $50 Million

January 10 2007

Targanta Therapeutics Inc. (f.k.a. PhageTech), a Cambridge, Mass.-based developer of antibacterial agents, is nearing a $50 million Series C deal, according to comments made by company CEO Mark Leuchtenberger during this week’s J.P. Morgan Healthcare Conference. http://www.targanta.com/

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Nearly there!

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.